Amneal Pharmaceuticals
AMRX
168 hedge funds and large institutions have $1.57B invested in Amneal Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 70 reducing their positions, and 23 closing their positions.
3,773% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $41K
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
6.62% more ownership
Funds ownership: 94.44% → 101.07% (+6.6%)
1% more funds holding
Funds holding: 167 → 168 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
35% less capital invested
Capital invested by funds: $2.41B → $1.57B (-$835M)
37% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 70
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$154M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$86.9M |
| 3 |
HM
HealthCor Management
New York
|
+$19.5M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$14.7M |
| 5 |
Renaissance Technologies
New York
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$49.2M |
| 2 |
BM
Bridger Management
New York
|
-$29.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.8M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$12.1M |
| 5 |
TA
Teachers Advisors
New York
|
-$10.7M |
AMRX Hedge Fund Activity: Q4 2018 in Review
168 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2018, worth a combined $1.57B — down 35% from $2.41B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AMRX positions and 23 closed out — a net gain of 3 holders — while 44 added to existing stakes and 70 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $154M. The largest seller was Fidelity Investments, cutting an estimated $49.2M.
- 168 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2018, up from 167 in Q3 2018.
- Funds reported $1.57B of Amneal Pharmaceuticals stock for Q4 2018, down 35% quarter-over-quarter.
- 26 funds opened new Amneal Pharmaceuticals positions in Q4 2018 and 23 closed out, a net change of +3 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2018 was T. Rowe Price Associates, an estimated $154M added.
- The largest Amneal Pharmaceuticals seller in Q4 2018 was Fidelity Investments, an estimated $49.2M sold.
Based on aggregated 13F filings for Q4 2018.